GSK plc
GSK
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $100.0B
$49.89
▼ -1.93%
P/E
15.34
Mkt Cap
$100.0B
52-Wk Range
$39.29–$61.70
52-Week Range
$39.29 - $61.70
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 24.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Value
Undervalued - trading well below sector peers
Momentum
Stable
-1.5% over 3m
Quality
Excellent
Strong fundamentals
Dividend
Solid
3.70% yield
Smart-money signal
Who's buying GSK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 28, 2026
Reported EPS of $1.36 vs $1.27 consensus (+7.1% surprise). Revenue of $11.2B vs $11.0B expected (+1.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+7.1%
Revenue trend · last 8Q
—
—
—
—
+7%
+6%
-1%
+5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$10.9B
$11.1B
$10.3B
$10.9B
$11.7B
$11.8B
$10.2B
$11.5B
Margins · last 8Q
Profit
5.2%
Wall Street consensus
3 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
67%
Sell
33%
Median Price Target
—
Latest: Morgan Stanley · Aug 25, 2026
vs Industry
How GSK stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.